MannKind presents Afrezza study at scientific meeting

ORLANDO, Fla. An inhaled insulin made by MannKind for patients with Type 2 diabetes provides glycemic control comparable to standard treatments, but with less weight gain, according to results of a study the company will present Saturday at a scientific meeting.

MannKind will present the study of Afrezza (insulin human [rDNA origin]) at a special symposium co-hosted by medical journal The Lancet and the American Diabetes Association at the ADA’s 70th annual Scientific Sessions. The study also will appear in the June 26 issue of The Lancet. The study compared Afrezza added to basal insulin with standard insulin therapy in adult patients with Type 2 diabetes to assess its ability to control post-meal blood sugar levels.

“Insulin therapy is often a delayed strategy in patients with Type 2 diabetes because it is associated with weight gain, hypoglycemia and the need for subcutaneous injections,” Diabetes Control Foundation executive and study co-author Daniel Lorber said. “Our findings show that mealtime Afrezza, in combination with once-daily injected glargine, provides equivalent glucose control with fewer injections, less hypoglycemia and less weight gain than does twice-a-day premixed insulin.”

Poll

Poll

Which of the current U.S. Presidential hopefuls do you think would be best for your business?

Hillary Clinton

Jeb Bush

Donald Trump

Ted Cruz

Ben Carson

Scott Walker

Marco Rubio

Rand Paul

Chris Christie

Mike Huckabee

SPECIAL REPORTS

Pharmacy’s battle for recognition continues

Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. To commemorate the anniversary, Drug Store News has put together an exclusive report on the effect that Medicare and Medicaid have had on the retail pharmacy industry and how it has transformed the role of the pharmacist. more...

IN THIS ISSUE

In this issue, DSN profiles Rite Aid and how the company is achieving a vision to become a retail healthcare company that delivers a higher level of care to its communities; takes you on a tour of Sears; offers insight into millennial shoppers and more. Click here to view the issue.